May manufacture insulin in the country for the sub-continent. Denmark-based Novo Nordisk, a world leader in diabetes care, is looking at India as a hub for manufacturing insulin for the entire sub-continent. The company today inaugurated a dedicated facility with a capacity of 26 million vials per annum in partnership with Ahmedabad-based Torrent Pharmaceuticals Ltd.

The Rs 1,600-crore Torrent Pharma is the flagship company of the Rs 6,400-crore Torrent Group and has been manufacturing insulin for Novo Nordisk since the early nineties.

Click here for Cloud Computing

Also Read   Related Stories News Now - Torrent Pharma plans to invest Rs 475 crore in Sikkim, Dahej - Novo Nordisk eyes India as insulin hub for sub-continent - MAT brings Torrent Pharma's net profit down by 69% - Torrent Pharma's net profit up by 36% for 2008-09

Also Read   Related Stories News Now - Markets end higher on firm global cues - Nuclear Iran: Anti-India stir gains ground in US - CBDT seeks review of SC ruling in Vodafone case - FMC awaits FCRA amendment to decide on pulses trading - Coal India decision to benefit Lanco's 5,000-MW capacity More

With over 50 million cases, India is one of the world's biggest markets for diabetes, and the numbers are expected to reach 80 million by 2025. While the adult prevalence rate in the country is at around 6.2 per cent, only a small percentage is actually treated.

Novo Nordisk enjoys a 70 per cent market share in the country, reaching out to almost 1.2 million people of the total two million patients who are currently getting treated with insulin. "India's share in Novo Nordisk's global turnover is negligible — around 1-1.5 per cent. But it is steadily growing at a rate of 20-30 per cent," Hoiland said. Novo Nordisk enjoys a 50 per cent share in the world insulin market.

Hoiland added, with the growing market in the country, India is fast becoming a strategic market for the company. Novo Nordisk has brought in 150 people from its Denmark operations and is currently holding 8-10 per cent of its clinical trials in India on over 10,000 people. Torrent Pharmaceuticals Chief Operating Officer Sanjay Dalal said his company had invested around $11 million on the dedicated insulin manufacturing facility for Novo Nordisk and this could be expanded. The Kadi facility could also be used to export insulin from India later on.

New Ipad Application :Business Standard's all new IPad App Click here to download for free Other Stories      - Markets end higher on firm global cues - Nuclear Iran: Anti-India stir gains ground in US - CBDT seeks review of SC ruling in Vodafone case - FMC awaits FCRA amendment to decide on pulses trading - Coal India decision to benefit Lanco's 5,000-MW capacity

Tags : Novo Nordisk | Torrent Pharmaceuticals | Jesper Hoiland   Read Business news in  Advertisements -  Now property search gets more exciting than ever before! -  High Growth Business Opportunities in Africa - Register to explore -  Medium-sized businesses are the engines of a smarter planet. -  Save over Rs.3000 with IndianOil Citibank Card -  India's No. 1 Property Site. Click here to know more.. -  Get 5% cashback on telephone bills with Citi -  Diseases earlier, Saving Costs, Extending Lives. Know More.. -  Enjoy the journey as much as the destination. click to know more.. -  Exim Bank Conclave on India - Africa Project Partnership. Know more.. -  Creating Wealth made simple the SIP way. Know more.. -  Only Developer to give a guarantee on time space & rate. -  Office 365 for professionals and small businesses. -  Buy Your Property with Our Triple Guarantee in India. -  Improve Patient Care & Experience. Click here to know more -  Win a Business Class Ticket to Europe..Know more.. -   Introduce a New Automotive Luxury Car.. know more